Hospital
ST. Davids Healthcare Partnership, L.P., LLP
ST. Davids Healthcare Partnership, L.P., LLP was paid $6.33M by Medicaid between Nov 2020 and Nov 2024, across 61 billing codes. Its largest line is 99284, emergency room visit (serious) — 61% of everything it billed.
33Billing provider infoST. DAVIDS HEALTHCARE PARTNERSHIP, L.P., LLP
AUSTIN, TX 78705
AUSTIN, TX 78705
33aNPI1720033947assigned 05/24/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.33M
24GClaims75,768
24DCodes billed61
24AFirst – last monthNov 2020 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#26 of 109
Median peer was paid$1.15M
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 683 | $93K | |
| 2021 | 18,601 | $1.35M | |
| 2022 | 25,004 | $2.11M | |
| 2023 | 22,069 | $2.15M | |
| 2024incomplete | 9,411 | $617K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 61% | 10,483 | 9,930 | $3.85M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 15,830 | 15,298 | $2.03M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 3,531 | 3,385 | $85K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 706 | 660 | $71K |
| 87400 | <1% | 2,419 | 2,267 | $49K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,031 | 1,870 | $48K |
| 80053 | Comprehensive metabolic panel | <1% | 6,860 | 6,367 | $43K |
| 85027 | <1% | 11,180 | 10,230 | $41K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,139 | 2,017 | $15K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 271 | 256 | $13K |
| 87430 | <1% | 739 | 696 | $9K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 834 | 833 | $8K |
49 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 1,185 | $8K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 52 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 341 | $7K |
| 81001 | <1% | 3,599 | $7K | |
| 76801 | <1% | 52 | $5K | |
| 81003 | <1% | 535 | $4K | |
| 83690 | <1% | 1,357 | $4K | |
| 84702 | <1% | 258 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,310 | $3K |
| 87081 | <1% | 403 | $3K | |
| 84484 | <1% | 1,421 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 27 | $2K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 112 | $2K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 15 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 200 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 35 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 935 | $1K |
| 84703 | <1% | 284 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 14 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 192 | $932.34 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 119 | $806.01 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 14 | $536.36 |
| 83880 | <1% | 170 | $489.04 | |
| 85730 | <1% | 432 | $458.70 | |
| 85610 | <1% | 618 | $358.15 | |
| 86901 | <1% | 186 | $326.36 | |
| 86900 | <1% | 187 | $326.28 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 299 | $322.02 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $293.80 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 15 | $192.66 |
| 87486 | <1% | 15 | $171.62 | |
| 87581 | <1% | 15 | $171.62 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 15 | $171.62 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 47 | $170.28 |
| 81025 | <1% | 40 | $169.15 | |
| 93017 | <1% | 74 | $157.39 | |
| 86850 | <1% | 15 | $99.28 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13 | $78.59 |
| 87420 | <1% | 13 | $65.10 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 502 | $56.98 |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 46 | $44.20 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16 | $9.36 |
| A9270 | Non-covered item or service | <1% | 2,775 | $0.70 |
| J2704 | Injection, propofol, 10 mg | <1% | 383 | $0.33 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 40 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 70 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 17 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 245 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCKNIGHT, DAVID (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sugar Land Surgery Center LTD | Sugar Land, TX | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.